<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02238210</url>
  </required_header>
  <id_info>
    <org_study_id>244.2503</org_study_id>
    <nct_id>NCT02238210</nct_id>
  </id_info>
  <brief_title>Safety Trial of Atrovent® in Pediatric Patients With Rhinorrhea Associated With a Common Cold or Allergy</brief_title>
  <official_title>A Phase IV Safety Trial in Pediatric Patients (Ages 2-5) With Rhinorrhea Associated With a Common Cold or Allergy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to determine the safety of Atrovent Nasal Spray 0.06% in pediatric patients (ages 2-5
      years) with symptoms of rhinorrhea associated with a naturally occurring common cold or from
      symptoms of rhinorrhea associated with allergies
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <primary_completion_date type="Actual">May 2003</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient's parent/legal guardian global assessment - common cold group</measure>
    <time_frame>Day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient's parent/legal guardian global assessment - allergy group</measure>
    <time_frame>Day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient's parent/legal guardian daily assessment of rhinorrhea (runny nose) rated on 5-point scale - common cold group</measure>
    <time_frame>Day 4</time_frame>
    <description>daily assessment by e-diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's parent/legal guardian daily assessment of nasal congestion (stuffy nose) rated on 5-point scale - common cold group</measure>
    <time_frame>Day 4</time_frame>
    <description>daily assessment by e-diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's parent/legal guardian daily assessment of sneezing rated on 5-point scale - common cold group</measure>
    <time_frame>Day 4</time_frame>
    <description>daily assessment by e-diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically findings in nasal and otoscopic examination - common cold group</measure>
    <time_frame>up to day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's parent/legal guardian daily assessment of rhinorrhea (runny nose) rated on 5-point scale - allergy group</measure>
    <time_frame>Day 14</time_frame>
    <description>daily assessment by e-diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's parent/legal guardian daily assessment of nasal congestion (stuffy nose) rated on 5-point scale - allergy group</measure>
    <time_frame>Day 14</time_frame>
    <description>daily assessment by e-diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's parent/legal guardian daily assessment of sneezing rated on 5-point scale - allergy group</measure>
    <time_frame>Day 14</time_frame>
    <description>daily assessment by e-diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically findings in nasal and otoscopic examination - allergy group</measure>
    <time_frame>up to day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">230</enrollment>
  <condition>Cold</condition>
  <arm_group>
    <arm_group_label>Atrovent® - common cold group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment duration for common cold group - three time daily for 4 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: Atrovent® - allergy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment duration for allergy group - three time daily for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atrovent®</intervention_name>
    <arm_group_label>Atrovent® - common cold group</arm_group_label>
    <arm_group_label>Experimental: Atrovent® - allergy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for patients with common cold

          -  Male or female at least 2 but not older than 5 years of age at screening

          -  Have a diagnosis of a common cold defined as presence of acute onset of rhinorrhea
             (within 48 hours of screening visit) and at least 1 of the following:

               -  Presence of swollen nasal membranes characteristic of a common cold on
                  examination at screening

               -  Presence of fever up to 102°F (oral or equivalent) within 48 hours of visit (may
                  be taken at home/away from the clinic) or at time of screening

          -  Capability of parent/legal guardian to read and understand the informed consent,
             record trial diary information, administer trial drug and read and understand trial
             assessment questionnaire

        Inclusion Criteria for patients with allergies

          -  Male or female at least 2 but not older than 5 year of age

          -  Have a diagnosis of seasonal or perennial allergic rhinitis defined as having both of
             the following:

               -  Positive skin or Radioallergosorbent test (RAST) test to a relevant allergen
                  within 12 months of screening or at the screening visit. For the purpose of this
                  trial a positive skin test is defined as wheal diameter that is at least 3 mm
                  greater than the negative control

               -  Positive prior history for atopy with nasal symptoms associated with expose to
                  allergens

          -  Symptoms associated with rhinorrhea for at least 48 hours prior to the screening visit

          -  Capability of parent/legal guardian to read and understand the informed consent,
             record trial diary information, administer trial drug and read and understand trial
             assessment questionnaire

        General Exclusion Criteria for both common cold and allergy

          -  Significant cardiovascular, renal, hepatic, endocrine, metabolic, neurologic or other
             systemic disease. A significant disease was defined as one which, in the opinion of
             the Investigator, either put the patient at risk because of participation in the trial
             or influenced the results of the trial or the patient's ability to participate in the
             trial

          -  Presence of rales or rhonchi suggestive of a lower respiratory tract infection

          -  An oral (or equivalent) temperature higher than 102°F

          -  Presence of otitis media

          -  Be initiating or advancing immunotherapy regimen during the course of this trial.
             Patients receiving a maintenance dose of immunotherapy are eligible

          -  Known intolerance to anticholinergics of hypersensitivity to benzalkonium chloride

          -  Excluded medications prior to Visit 1 and during the trial included:

               1. 24 hours before

                    -  Over-the-counter decongestants or nasal/ocular cromolyn

               2. 3 days before:

                    -  Anticholinergics

                    -  Over-the-counter antihistamines

                    -  sympathomimetic decongestants

               3. 5 days before:

                    -  Fexofenadine

                    -  Loratadine

               4. 7 days before:

                    -  Cetirizine

                    -  antihistamines such as Atarax® or doxepin hydrochloride

                    -  Antidepressants

               5. 14 days before:

                    -  Intranasal steroids

               6. 28 days before:

                    -  Steroids (oral and injectable)

                    -  Leukotriene modifiers (e.g. Accolate®, Singulair®)

                    -  Other investigational drugs

          -  Participation in any trial with an investigational drug within 30 days of the
             screening visit

          -  Nasal obstruction greater than 50% that would prevent deposition of trial drug

          -  The parent/legal guardian has a disability or lives in a geographical location that
             could impair compliance with the protocol or visits to the trial center

        Exclusion criteria for patients with a common cold

          -  History or perennial allergic rhinitis or seasonal allergic rhinitis (SAR) with
             allergen in season

          -  Positive Streptococcus test

        Exclusion criteria for patients with allergies

          -  Patients with active infectious rhinitis (common cold) as determined by history and
             physical

          -  Patients with upper or lower respiratory infection at screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2014</study_first_submitted>
  <study_first_submitted_qc>September 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2014</study_first_posted>
  <last_update_submitted>September 11, 2014</last_update_submitted>
  <last_update_submitted_qc>September 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Common Cold</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ipratropium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

